Emcure Pharmaceuticals Limited has received an independent Environmental, Social, and Governance (ESG) rating of 21 for the Financial Year 2024-25. The rating was assigned by NSE Sustainability Ratings & Analytics Limited, based on publicly available information. This voluntary assessment reflects the company’s commitment to transparency and its ongoing efforts to align with global ESG standards in its corporate operations.
ESG Rating Assessment
Emcure Pharmaceuticals Limited has been assigned an ESG rating of 21 by NSE Sustainability Ratings & Analytics Limited. This independent assessment, provided to the company on May 07, 2026, evaluates the firm’s performance across key sustainability pillars for the Financial Year 2024-25. The rating process was conducted independently by the ESG Rating Provider, utilizing data sourced entirely from the public domain.
Commitment to Transparency
By undergoing this voluntary rating process, Emcure Pharmaceuticals aims to enhance its corporate disclosure framework and provide stakeholders with greater insight into its sustainability practices. The score of 21 serves as a benchmark for the company as it continues to integrate Environmental, Social, and Governance considerations into its long-term business strategy.
Source: BSE
